Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 6/20 | 0.69 |
| ▸ | BCHE known ✓ | P06276 | 3/20 | 0.69 |
| ▸ | CACNA1F known ✓ | O60840 | 1/20 | 0.67 |
| ▸ | PDE5A known ✓ | O76074 | 1/20 | 0.67 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.67 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.67 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.67 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.67 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.67 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.67 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.67 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.67 |
| ▸ | AGTR1 known ✓ | P30556 | 1/20 | 0.67 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.67 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.67 |
| ▸ | CACNA1D known ✓ | Q01668 | 1/20 | 0.67 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.67 |
| ▸ | CHRNE known ✓ | Q04844 | 1/20 | 0.67 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.67 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4196384 | 0.99 | ACHE (0.70) | ACHEBCHEKDM4EFAAHABCC4 | |
| SCHEMBL13854687 | 0.90 | ACHE (0.67) | ACHEBCHEKDM4EFAAHABCC4 | |
| Hydrochloric Acid SCHEMBL7836184 | 0.89 | SIGMAR1 (0.63) | ACHESIGMAR1 | |
| SCHEMBL7829371 | 0.88 | SIGMAR1 (0.65) | ACHESIGMAR1 | |
| Hydrochloric Acid SCHEMBL4203132 | 0.84 | BCHE (0.76) | ACHEBCHEKDM4EFAAHABCC4 | |
| SCHEMBL8077491 | 0.83 | BCHE (0.72) | ACHEBCHEKDM4EFAAHABCC4 | |
| SCHEMBL8229169 | 0.83 | BCHE (0.75) | ACHEBCHEKDM4EFAAHABCC4 | |
| SCHEMBL11913989 | 0.83 | BCHE (0.75) | ACHEBCHEKDM4EFAAHABCC4 | |
| SCHEMBL24390900 | 0.82 | BCHE (0.74) | ACHEBCHEKDM4EFAAHABCC4 | |
| SCHEMBL4838247 | 0.82 | BCHE (0.76) | ACHEBCHEKDM4EFAAHABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107709326-A | Reduce the P TAU of stress-induced Triazolopyridine and triazolo pyrimidine | 巴克老龄问题研究所 | 2018-02-16 | — | — | CN | disclosed |
| US-20090137629-A1 | Sigma receptor binding agent containing indanone derivative | IIMURA YOICHI | 2009-05-28 | — | — | US | disclosed |
| US-20050107432-A1 | Sigma receptor binder containing indanone derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-05-19 | — | — | US | disclosed |
| EP-1468684-A1 | SIGMA RECEPTOR BINDER CONTAINING INDANONE DERIVATIVE | Eisai Co., Ltd. (JP) | 2004-10-20 | — | — | EP | disclosed |
| US-6492522-B1 | OPTICAL ISOMERS AND SALTS WITH 4-PYRIDINECARBOXALDEHYDE IN THE PRESENCE OF BASE TO GIVE A COMPOUND OF THE FORMULA REACTING THE COMPOUND OBTAINED IN STEP B) ABOVE OR A SALT THEREOF WITH A COMPOUND OF FORMULA R.SUP.10 X, WHEREIN R.SUP.10, | FINETECH LABORATORIES LTD. (IL) | 2002-12-10 | — | — | US | disclosed |
| EP-1129073-A2 | PROCESS AND INTERMEDIATES FOR PRODUCTION OF DONEPEZIL AND RELATED COMPOUNDS | Finetech Ltd (IL) | 2001-09-05 | — | — | EP | disclosed |
| WO-2000009483-A2 | PROCESS AND INTERMEDIATES FOR PRODUCTION OF DONEPEZIL AND RELATED COMPOUNDS | FINETECH LTD. (IL) | 2000-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137629-A1 | Sigma receptor binding agent containing indanone derivative | SIGMAR1, TMEM97, OPRK1 | ACHE 608/4885BCHE 1667/4885CACNA1F 1576/4885 |
| US-20050107432-A1 | Sigma receptor binder containing indanone derivative | SIGMAR1, OPRK1, TMEM97 | ACHE 2667/4885BCHE 3026/4885CACNA1F 1932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.